Kala Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net income was USD 29.07 million compared to net loss of USD 28.13 million a year ago. Basic earnings per share from continuing operations was USD 19.39 compared to basic loss per share from continuing operations of USD 21.41 a year ago. Diluted earnings per share from continuing operations was USD 19.25 compared to diluted loss per share from continuing operations of USD 21.41 a year ago.
For the nine months, net loss was USD 31.98 million compared to USD 95.04 million a year ago. Basic loss per share from continuing operations was USD 21.46 compared to USD 73.8 a year ago. Diluted loss per share from continuing operations was USD 21.46 compared to USD 73.8 a year ago.